MedTrace Logo

Comparative Evaluation of Covid-19 Vaccines Response

NCT04895007 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1500

Last updated 2021-07-15

No results posted yet for this study

Summary

Study Population

Population with vaccinated with three different Covid Vaccines (Inactive Vaccine (Sinovac Life Sciences, Beijing, China), recombinant human adenovirus serotype number 26 (rAd26 of Sputnik V), mRNA Vaccine (Pfizer/BionTEC). This is multi center study, 5 centers will be joined to study from different part of the country. Approximately 1500 people will be enrolled to study.

Conditions

  • COVID-19 Vaccines

Interventions

BIOLOGICAL

Covid-19 Inactive Vaccine, recombinant human adenovirus serotype number 26, mRNA VAccine

Anti-SARS-CoV-2 IgG Antibody and Neutralizing Antibody will be evaluated 2, 6, 12 Months after second dose.

Sponsors & Collaborators

  • Karamanoğlu Mehmetbey University

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-06-01
Primary Completion
2022-06-01
Completion
2022-06-01

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04895007 on ClinicalTrials.gov